Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Monobody Inhibitor Selective to the Phosphatase Domain of SHP2 and its Use as a Probe for Quantifying SHP2 Allosteric Regulation.

Journal of molecular biology - 15 Apr 2023

Sha Fern, Kurosawa Kohei, Glasser Eliezra, Ketavarapu Gayatri, Albazzaz Samara, Koide Akiko, Koide Shohei

Abstract excerpt

SHP2 is a phosphatase/adaptor protein that plays an important role in various signaling pathways. Its mutations are associated with cancers and developmental diseases. SHP2 contains a protein tyrosine phosphatase (PTP) and two SH2 domains. Selective inhibition of these domains has been challenging due to the multitude of homologous proteins in the proteome. Here, we developed a monobody, synthetic binding...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allosteric Regulation
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Mutation

Share to Neoplasms

Share to Protein Domains

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 36806475
DOI: 10.1016/j.jmb.2023.168010
PMCID: PMC10079645

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Monobody Inhibitor Selective to the Phosphatase Domain of SHP2 and its Use as a Probe for Quantifying SHP2 Allosteric Regulation.PMID 36806475Read ↗

The Landscape of Protein Tyrosine Phosphatase (Shp2) and CancerSemantic proximity Read ↗

Allosteric Inhibitors of SHP2: An Updated Patent Review (2015-2020).Semantic proximity Read ↗

Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.Semantic proximity Read ↗

Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase InterfaceSemantic proximity Read ↗

The pathogenic T42A mutation in SHP2 rewires the interaction specificity of its N-terminal regulatory domainSemantic proximity Read ↗

Targeting Oncogenic Src Homology 2 Domain-Containing Phosphatase 2 (SHP2) by Inhibiting its Protein-Protein InteractionsSemantic proximity Read ↗

Targeting Oncogenic Src Homology 2 Domain-Containing Phosphatase 2 (SHP2) by Inhibiting Its Protein-Protein Interactions.Semantic proximity Read ↗

An allosteric interaction controls the activation mechanism of SHP2 tyrosine phosphatase.Semantic proximity Read ↗

Targeting SHP2 phosphatase in hematological malignancies.Semantic proximity Read ↗

The pathogenic T42A mutation in SHP2 rewires the interaction specificity of its N-terminal regulatory domain.Semantic proximity Read ↗

Targeting SHP2 Cryptic Allosteric Sites for Effective Cancer Therapy.Semantic proximity Read ↗

Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.